Watertown biotech plans first clinical trial of weeklong schizophrenia drug

Watertown-based startup Lyndra Therapeutics is planning to launch its first clinical trial next year after early testing showed its science could turn a once-daily pill into a weekly treatment.

Lyndra is testing a new science that can extend chronic oral medications from a once-daily treatment to a weekly regimen. The three-year-old biotech startup originated out of MIT professor [Bob Langer](https://www.bizjournals.com/boston/search/results?q=Bob Langer)'s lab and has received support from the Bill and Melinda Gates Foundation.

The company announced Thursday that an early clinical study involving nearly 50 people showed that the medication formula could extend the effects of a drug out over seven days. Lyndra plans to file an application with the FDA next year to begin clinical trials on a once-a-week schizophrenia drug.

https://www.bizjournals.com/boston/news/2018/11/15/watertown-biotech-plans-first-clinical-trial-of.html

2 Likes